Microbion Corporation
Pharmaceuticals, 5 W Mendenhall St, Bozeman, Montana, 59715, United States, 1-10 Employees
Phone Number: 14*********
Who is MICROBION CORPORATION
Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds to improve the lives of patients with rare and serious diseases. Microbions lead drug ...
Read More
-
Headquarters: 5 W Mendenhall St, Bozeman, Montana, 59715, United States
-
Date Founded: 2000
-
Employees: 1-10
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 8731
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from MICROBION CORPORATION
Microbion Corporation Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Microbion Corporation
Answer: Microbion Corporation's headquarters are located at 5 W Mendenhall St, Bozeman, Montana, 59715, United States
Answer: Microbion Corporation's phone number is 14*********
Answer: Microbion Corporation's official website is https://microbioncorp.com
Answer: Microbion Corporation's revenue is $10 Million to $25 Million
Answer: Microbion Corporation's SIC: 8731
Answer: Microbion Corporation's NAICS: 541714
Answer: Microbion Corporation has 1-10 employees
Answer: Microbion Corporation is in Pharmaceuticals
Answer: Microbion Corporation contact info: Phone number: 14********* Website: https://microbioncorp.com
Answer: Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds to improve the lives of patients with rare and serious diseases. Microbions lead drug candidate, pravibismane, is the first product in this new class and has a novel mechanism of action offering the unique potential to address the unmet needs of chronic and severe health conditions. We plan to advance inhaled pravibismane in Phase 1 clinical development to treat chronic lung diseases, including non-tuberculous mycobacteria (NTM) and cystic fibrosis-related lung infections. Topical/local pravibismane is in Phase 2 development for the treatment of chronic wounds and orthopedic infections. Pravibismane has received backing from the Cystic Fibrosis Foundation, NIH, US DoD, and CARB-X with over $21 million in grants. The FDA has granted pravibismane with Orphan Drug, Fast Track, and QIDP designations. Pravibismane is potent against a broad spectrum of pathogens, including Gram -positive and Gram -negative bacteria, fungal pathogens, and multidrug-resistant priority pathogens or superbugs identified by the US CDC. Furthermore, pravibismane has an unprecedented ability to prevent and eradicate microbial biofilms that contribute to resistance and chronic disease. Microbions site-specific delivery approach enables greater efficacy by achieving a higher therapeutic concentration of drug at the site of infection, improved safety, and a lower risk of developing antibiotic resistance associated with systemic antibiotic administration.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month